Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 705 entries
Sorted by: Best Match Show Resources per page
Comparative effectiveness research and measuring the level of pharmaceutical innovation in the EU.

Journal of comparative effectiveness research

Annemans L, Cleemput I, Hulstaert F, Simoens S.
PMID: 24237295
J Comp Eff Res. 2012 Jan;1(1):19-29. doi: 10.2217/cer.11.1.

Over the past 50 years, medicines have made a huge contribution to improving the health status of populations. However, the level of pharmaceutical innovation varies widely, ranging from breakthrough treatments for life-threatening diseases to minor modifications of medicines that...

Cite
Annemans L, Cleemput I, Hulstaert F, et al. Comparative effectiveness research and measuring the level of pharmaceutical innovation in the EU. J Comp Eff Res. 2012;1(1):19-29doi: 10.2217/cer.11.1.
Annemans, L., Cleemput, I., Hulstaert, F., & Simoens, S. (2012). Comparative effectiveness research and measuring the level of pharmaceutical innovation in the EU. Journal of comparative effectiveness research, 1(1), 19-29. https://doi.org/10.2217/cer.11.1
Annemans, Lieven, et al. "Comparative effectiveness research and measuring the level of pharmaceutical innovation in the EU." Journal of comparative effectiveness research vol. 1,1 (2012): 19-29. doi: https://doi.org/10.2217/cer.11.1
Annemans L, Cleemput I, Hulstaert F, Simoens S. Comparative effectiveness research and measuring the level of pharmaceutical innovation in the EU. J Comp Eff Res. 2012 Jan;1(1):19-29. doi: 10.2217/cer.11.1. PMID: 24237295.
Copy Download .nbib Format: NLM
Preface. Novel targets and drugs to prevent atherogenesis and its consequences.

European journal of pharmacology

Riksen NP, Rongen GA.
PMID: 26370897
Eur J Pharmacol. 2015 Sep 15;763:1-2. doi: 10.1016/j.ejphar.2015.08.042.

No abstract available.

Cite
Riksen NP, Rongen GA. Preface. Novel targets and drugs to prevent atherogenesis and its consequences. Eur J Pharmacol. 2015;763:1-2doi: 10.1016/j.ejphar.2015.08.042.
Riksen, N. P., & Rongen, G. A. (2015). Preface. Novel targets and drugs to prevent atherogenesis and its consequences. European journal of pharmacology, 7631-2. https://doi.org/10.1016/j.ejphar.2015.08.042
Riksen, Niels P, and Rongen, Gerard A. "Preface. Novel targets and drugs to prevent atherogenesis and its consequences." European journal of pharmacology vol. 763 (2015): 1-2. doi: https://doi.org/10.1016/j.ejphar.2015.08.042
Riksen NP, Rongen GA. Preface. Novel targets and drugs to prevent atherogenesis and its consequences. Eur J Pharmacol. 2015 Sep 15;763:1-2. doi: 10.1016/j.ejphar.2015.08.042. PMID: 26370897.
Copy Download .nbib Format: NLM
No Denying It: Medicinal Chemistry Training Is in Big Trouble.

Journal of medicinal chemistry

Rafferty MF.
PMID: 27668824
J Med Chem. 2016 Dec 22;59(24):10859-10864. doi: 10.1021/acs.jmedchem.6b00741. Epub 2016 Oct 07.

There has been little consensus between the pharmaceutical industry and academic communities concerning the best approach to train medicinal chemists for drug discovery. For decades the pharmaceutical industry has shown preference for synthetic organic graduates over candidates with degrees...

Cite
Rafferty MF. No Denying It: Medicinal Chemistry Training Is in Big Trouble. J Med Chem. 2016;59(24):10859-10864doi: 10.1021/acs.jmedchem.6b00741.
Rafferty, M. F. (2016). No Denying It: Medicinal Chemistry Training Is in Big Trouble. Journal of medicinal chemistry, 59(24), 10859-10864. https://doi.org/10.1021/acs.jmedchem.6b00741
Rafferty, Michael F. "No Denying It: Medicinal Chemistry Training Is in Big Trouble." Journal of medicinal chemistry vol. 59,24 (2016): 10859-10864. doi: https://doi.org/10.1021/acs.jmedchem.6b00741
Rafferty MF. No Denying It: Medicinal Chemistry Training Is in Big Trouble. J Med Chem. 2016 Dec 22;59(24):10859-10864. doi: 10.1021/acs.jmedchem.6b00741. Epub 2016 Oct 07. PMID: 27668824.
Copy Download .nbib Format: NLM
Editorial (Thematic Issue: Polypharmacology in Drug Discovery).

Current pharmaceutical design

Scotti L, Scotti MT.
PMID: 27291593
Curr Pharm Des. 2016;22(21):3071-2.

No abstract available.

Cite
Scotti L, Scotti MT. Editorial (Thematic Issue: Polypharmacology in Drug Discovery). Curr Pharm Des. 2016;22(21):3071-2
Scotti, L., & Scotti, M. T. (2016). Editorial (Thematic Issue: Polypharmacology in Drug Discovery). Current pharmaceutical design, 22(21), 3071-2.
Scotti, Luciana, and Scotti, Marcus T. "Editorial (Thematic Issue: Polypharmacology in Drug Discovery)." Current pharmaceutical design vol. 22,21 (2016): 3071-2.
Scotti L, Scotti MT. Editorial (Thematic Issue: Polypharmacology in Drug Discovery). Curr Pharm Des. 2016;22(21):3071-2. PMID: 27291593.
Copy Download .nbib Format: NLM
Epigenetic Drug Discovery: Great Potential and Significant Challenges.

Assay and drug development technologies

Cummings R.
PMID: 26065555
Assay Drug Dev Technol. 2015 May;13(4):185. doi: 10.1089/adt.2015.29000.rcu.

No abstract available.

Cite
Cummings R. Epigenetic Drug Discovery: Great Potential and Significant Challenges. Assay Drug Dev Technol. 2015;13(4):185doi: 10.1089/adt.2015.29000.rcu.
Cummings, R. (2015). Epigenetic Drug Discovery: Great Potential and Significant Challenges. Assay and drug development technologies, 13(4), 185. https://doi.org/10.1089/adt.2015.29000.rcu
Cummings, Rich. "Epigenetic Drug Discovery: Great Potential and Significant Challenges." Assay and drug development technologies vol. 13,4 (2015): 185. doi: https://doi.org/10.1089/adt.2015.29000.rcu
Cummings R. Epigenetic Drug Discovery: Great Potential and Significant Challenges. Assay Drug Dev Technol. 2015 May;13(4):185. doi: 10.1089/adt.2015.29000.rcu. PMID: 26065555.
Copy Download .nbib Format: NLM
Novel approaches to address challenges in global drug development.

Clinical pharmacology and therapeutics

Smith BP, Huang SM.
PMID: 25669768
Clin Pharmacol Ther. 2015 Mar;97(3):196-9. doi: 10.1002/cpt.62. Epub 2015 Jan 22.

No abstract available.

Cite
Smith BP, Huang SM. Novel approaches to address challenges in global drug development. Clin Pharmacol Ther. 2015;97(3):196-9doi: 10.1002/cpt.62.
Smith, B. P., & Huang, S. M. (2015). Novel approaches to address challenges in global drug development. Clinical pharmacology and therapeutics, 97(3), 196-9. https://doi.org/10.1002/cpt.62
Smith, B P, and Huang, S-M. "Novel approaches to address challenges in global drug development." Clinical pharmacology and therapeutics vol. 97,3 (2015): 196-9. doi: https://doi.org/10.1002/cpt.62
Smith BP, Huang SM. Novel approaches to address challenges in global drug development. Clin Pharmacol Ther. 2015 Mar;97(3):196-9. doi: 10.1002/cpt.62. Epub 2015 Jan 22. PMID: 25669768.
Copy Download .nbib Format: NLM
Public-Private Partnerships in Lead Discovery: Overview and Case Studies.

Archiv der Pharmazie

Gottwald M, Becker A, Bahr I, Mueller-Fahrnow A.
PMID: 27335205
Arch Pharm (Weinheim). 2016 Sep;349(9):692-7. doi: 10.1002/ardp.201600078. Epub 2016 Jun 23.

The pharmaceutical industry is faced with significant challenges in its efforts to discover new drugs that address unmet medical needs. Safety concerns and lack of efficacy are the two main technical reasons for attrition. Improved early research tools including...

Cite
Gottwald M, Becker A, Bahr I, et al. Public-Private Partnerships in Lead Discovery: Overview and Case Studies. Arch Pharm (Weinheim). 2016;349(9):692-7doi: 10.1002/ardp.201600078.
Gottwald, M., Becker, A., Bahr, I., & Mueller-Fahrnow, A. (2016). Public-Private Partnerships in Lead Discovery: Overview and Case Studies. Archiv der Pharmazie, 349(9), 692-7. https://doi.org/10.1002/ardp.201600078
Gottwald, Matthias, et al. "Public-Private Partnerships in Lead Discovery: Overview and Case Studies." Archiv der Pharmazie vol. 349,9 (2016): 692-7. doi: https://doi.org/10.1002/ardp.201600078
Gottwald M, Becker A, Bahr I, Mueller-Fahrnow A. Public-Private Partnerships in Lead Discovery: Overview and Case Studies. Arch Pharm (Weinheim). 2016 Sep;349(9):692-7. doi: 10.1002/ardp.201600078. Epub 2016 Jun 23. PMID: 27335205.
Copy Download .nbib Format: NLM
Chemical Space: Big Data Challenge for Molecular Diversity.

Chimia

Awale M, Visini R, Probst D, Arús-Pous J, Reymond JL.
PMID: 29070411
Chimia (Aarau). 2017 Oct 25;71(10):661-666. doi: 10.2533/chimia.2017.661.

Chemical space describes all possible molecules as well as multi-dimensional conceptual spaces representing the structural diversity of these molecules. Part of this chemical space is available in public databases ranging from thousands to billions of compounds. Exploiting these databases...

Cite
Awale M, Visini R, Probst D, et al. Chemical Space: Big Data Challenge for Molecular Diversity. Chimia (Aarau). 2017;71(10):661-666doi: 10.2533/chimia.2017.661.
Awale, M., Visini, R., Probst, D., Arús-Pous, J., & Reymond, J. L. (2017). Chemical Space: Big Data Challenge for Molecular Diversity. Chimia, 71(10), 661-666. https://doi.org/10.2533/chimia.2017.661
Awale, Mahendra, et al. "Chemical Space: Big Data Challenge for Molecular Diversity." Chimia vol. 71,10 (2017): 661-666. doi: https://doi.org/10.2533/chimia.2017.661
Awale M, Visini R, Probst D, Arús-Pous J, Reymond JL. Chemical Space: Big Data Challenge for Molecular Diversity. Chimia (Aarau). 2017 Oct 25;71(10):661-666. doi: 10.2533/chimia.2017.661. PMID: 29070411.
Copy Download .nbib Format: NLM
23andMe wades further into drug discovery.

Nature biotechnology

Petrone J.
PMID: 29020001
Nat Biotechnol. 2017 Oct 11;35(10):897. doi: 10.1038/nbt1017-897.

No abstract available.

Cite
Petrone J. 23andMe wades further into drug discovery. Nat Biotechnol. 2017;35(10):897doi: 10.1038/nbt1017-897.
Petrone, J. (2017). 23andMe wades further into drug discovery. Nature biotechnology, 35(10), 897. https://doi.org/10.1038/nbt1017-897
Petrone, Justin. "23andMe wades further into drug discovery." Nature biotechnology vol. 35,10 (2017): 897. doi: https://doi.org/10.1038/nbt1017-897
Petrone J. 23andMe wades further into drug discovery. Nat Biotechnol. 2017 Oct 11;35(10):897. doi: 10.1038/nbt1017-897. PMID: 29020001.
Copy Download .nbib Format: NLM
A Brief Review of Computer-Assisted Approaches to Rational Design of Peptide Vaccines.

International journal of molecular sciences

Nandy A, Basak SC.
PMID: 27153063
Int J Mol Sci. 2016 May 04;17(5). doi: 10.3390/ijms17050666.

The growing incidences of new viral diseases and increasingly frequent viral epidemics have strained therapeutic and preventive measures; the high mutability of viral genes puts additional strains on developmental efforts. Given the high cost and time requirements for new...

Cite
Nandy A, Basak SC. A Brief Review of Computer-Assisted Approaches to Rational Design of Peptide Vaccines. Int J Mol Sci. 2016;17(5)doi: 10.3390/ijms17050666.
Nandy, A., & Basak, S. C. (2016). A Brief Review of Computer-Assisted Approaches to Rational Design of Peptide Vaccines. International journal of molecular sciences, 17(5), . https://doi.org/10.3390/ijms17050666
Nandy, Ashesh, and Basak, Subhash C. "A Brief Review of Computer-Assisted Approaches to Rational Design of Peptide Vaccines." International journal of molecular sciences vol. 17,5 (2016). doi: https://doi.org/10.3390/ijms17050666
Nandy A, Basak SC. A Brief Review of Computer-Assisted Approaches to Rational Design of Peptide Vaccines. Int J Mol Sci. 2016 May 04;17(5). doi: 10.3390/ijms17050666. PMID: 27153063; PMCID: PMC4881492.
Copy Download .nbib Format: NLM
An incentive-based approach for improving data reproducibility.

Science translational medicine

Rosenblatt M.
PMID: 27122610
Sci Transl Med. 2016 Apr 27;8(336):336ed5. doi: 10.1126/scitranslmed.aaf5003.

No abstract available.

Cite
Rosenblatt M. An incentive-based approach for improving data reproducibility. Sci Transl Med. 2016;8(336):336ed5doi: 10.1126/scitranslmed.aaf5003.
Rosenblatt, M. (2016). An incentive-based approach for improving data reproducibility. Science translational medicine, 8(336), 336ed5. https://doi.org/10.1126/scitranslmed.aaf5003
Rosenblatt, Michael. "An incentive-based approach for improving data reproducibility." Science translational medicine vol. 8,336 (2016): 336ed5. doi: https://doi.org/10.1126/scitranslmed.aaf5003
Rosenblatt M. An incentive-based approach for improving data reproducibility. Sci Transl Med. 2016 Apr 27;8(336):336ed5. doi: 10.1126/scitranslmed.aaf5003. PMID: 27122610.
Copy Download .nbib Format: NLM
Molecular dynamics: new advances in drug discovery.

European journal of medicinal chemistry

Milardi D, Pappalardo M.
PMID: 25466447
Eur J Med Chem. 2015 Feb 16;91:1-3. doi: 10.1016/j.ejmech.2014.10.078. Epub 2014 Nov 01.

No abstract available.

Cite
Milardi D, Pappalardo M. Molecular dynamics: new advances in drug discovery. Eur J Med Chem. 2014;91:1-3doi: 10.1016/j.ejmech.2014.10.078.
Milardi, D., & Pappalardo, M. (2015). Molecular dynamics: new advances in drug discovery. European journal of medicinal chemistry, 911-3. https://doi.org/10.1016/j.ejmech.2014.10.078
Milardi, Danilo, and Pappalardo, Matteo. "Molecular dynamics: new advances in drug discovery." European journal of medicinal chemistry vol. 91 (2015): 1-3. doi: https://doi.org/10.1016/j.ejmech.2014.10.078
Milardi D, Pappalardo M. Molecular dynamics: new advances in drug discovery. Eur J Med Chem. 2015 Feb 16;91:1-3. doi: 10.1016/j.ejmech.2014.10.078. Epub 2014 Nov 01. PMID: 25466447.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 705 entries